CSF Biomarkers for Alzheimer’s Disease: Levels of β-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival

Cerebrospinal fluid (CSF) samples from 21 patients with a clinical diagnosis of Alzheimer’s disease (AD) participating in a 5-year treatment study with the choline esterase inhibitor tacrin were retrospectively analyzed for the contents of β-amyloid (Aβ42), total tau (T-tau) and phosphorylated tau (P-tau). A significant positive correlation between the level of P-tau and the number of symptoms according to the DSM-IV criteria (p = 0.041) and the NINCDS-ADRDA (p = 0.029) was observed (i.e. higher levels were found in cases with more symptoms). A significant positive correlation between T-tau, P-tau and ADAS-cog score was identified (i.e. higher levels were found with more severe cognitive dysfunction). Patients who died during the 5-year follow-up had significantly lower levels of Aβ42 (p = 0.011) than those who were still alive. Patients who had died in a 6-year follow-up had significantly lower levels of Aβ42 (p = 0.034) and higher levels of T-tau (p = 0.041) than patients still alive. Conclusion: CSF biomarkers do aid the clinical diagnosis of AD. Increased levels of P-tau and T-tau are possible markers for severity and abundance of symptoms in AD. Low levels of Aβ42 may indicate a higher risk of early death in AD.

[1]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[2]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan , 1998 .

[3]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[4]  L. Parnetti,et al.  CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies , 2001, Neurological Sciences.

[5]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[6]  D. Riesner,et al.  Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy , 1998, Nature Medicine.

[7]  C. Wattmo,et al.  Five-Year Outcome of Cholinergic Treatment of Alzheimer’s Disease: Early Response Predicts Prolonged Time until Nursing Home Placement, but Does Not Alter Life Expectancy , 2004, Dementia and Geriatric Cognitive Disorders.

[8]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. , 1998, Annals of neurology.

[9]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[10]  K. Blennow,et al.  Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. , 1999, Neurology.

[11]  T. Iwatsubo,et al.  Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.

[12]  A. Brun,et al.  Distribution of cerebral degeneration in Alzheimer's disease , 1976, Archiv für Psychiatrie und Nervenkrankheiten.

[13]  H. Soininen,et al.  The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease , 1997, Neuroreport.

[14]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[15]  Á. Hernanz,et al.  Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[16]  R. Wolfert,et al.  Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .

[17]  R. Heun,et al.  Mortality in Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[18]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[19]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[20]  Nancy Reagan,et al.  Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease" , 1998 .

[21]  K. Blennow,et al.  Both total and phosphorylated tau are increased in Alzheimer's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[22]  D. Knopman,et al.  Cerebrospinal fluid beta-amyloid and tau proteins for the diagnosis of Alzheimer disease. , 2001, Archives of neurology.

[23]  W. Snow,et al.  The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimerʼs disease: a clinicopathologic study of 57 cases , 1988 .

[24]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[25]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[26]  Henrik Zetterberg,et al.  APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42 , 2004, Neurology.

[27]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Neurology.

[28]  K. Blennow,et al.  Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[29]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[30]  L A Hansen,et al.  Clinical-neuropathological correlations in Alzheimer's disease and related dementias. , 1994, Archives of neurology.

[31]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[32]  H. Arai,et al.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects , 2002, Neurology.

[33]  K. Blennow,et al.  Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.

[34]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[35]  Khadija Iqbal,et al.  Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. , 1993, Archives of biochemistry and biophysics.

[36]  K. Blennow,et al.  Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment , 1999, Neuroscience Letters.

[37]  K. Blennow,et al.  Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke , 2001, Neuroscience Letters.

[38]  Kaj Blennow,et al.  β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease , 2002, Peptides.

[39]  R. Brookmeyer,et al.  APOE genotype and survival in men and women with Alzheimer’s disease , 2002, Neurology.

[40]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[41]  J. Trojanowski,et al.  Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease , 1995, Annals of neurology.

[42]  D. Galasko,et al.  Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease , 1997, Neurology.

[43]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[44]  R. Mohs,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). , 1995, Neurology.

[45]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.